Substance abuse, testing

Percentage of workers failing random substance abuse tests X ... 

Kwong, TC, Chamberlain RT, Frederick DL, Kapur B, Sunshine I. Critical issues in urinalysis of abused substances Report of the substance-abuse testing committee. Clin Chem 1988 34 605-32. 

Descriptions of the contractor s various safety programs, inciuding accident investigation procedures how safety HSE inspections are performed safety meetings substance abuse testing, inspection and preventive maintenance programs... 

Safety Programs and Procedures Identifies the Contractor s safety programs and policies and provides information on the Contractor s substance abuse testing program. 

Companies generally require that all contractors have a drug and alcohol program and that each contractor employee be tested annually and before entering the company s premises. (Contractors or vendors whose need for site access poses a minimal safety risk may be exempted from preaccess substance abuse testing.) Contractor employees can also be tested upon reasonable suspicion by the contractor or company that an employee has consumed any prohibited substance. 

Medical Evaluation," restates the requirement to follow the American National Standards Institute/American Nuclear Society (ANSI/ANS) standard. WSRC-1-03 states that NRC Form 396, "Certificate of Medical Examination" or a suitable alternative may be used. The form actually used is found in the WSRC Medical Department Manual, WSRC Q3.6-Substance Abuse Testing, Procedure 1004. 

WSRC, Medical Department Manual Q3.6-Substance Abuse Testing, Procedures 1002, 1003, 1004, and 1007. 

Ciraulo DA, Jaffe JH Tricyclic antidepressants in the treatment of depression associated with alcoholism. Clin Psychopharmacol 1 146—150, 1981 Ciraulo DA, Nace E Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 9 276—284, 2000 Ciraulo DA, Barnhill JG, Jaffe JH, et al Intravenous pharmacokinetics of 2-hydroxy-imipramine in alcoholics and normal controls. J StudAlcohol 51 366-372, 1990 Ciraulo DA, Knapp CM, LoCastro J, et al A benzodiazepine mood effect scale reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 27 339—347, 2001 Collins MA Tetrahydropapaveroline in Parkinson s disease and alcoholism a look back in honor of Merton Sandler. Neurotoxicology 25 117-120, 2004 COMBINE Study Research Group Testing combined pharmacotherapies and behavioral interventions in alcohol dependence rationale and methods. Alcohol Clin Exp Res 27 1107-1122, 2003a... 

J Consult Clin Psychol 61 1100—1104, 1993 Stephens RS, Roffman RA, Simpson EE Treating adult marijuana dependence a test of the relapse prevention model. J Consult Clin Psychol 62 92—99, 1994 Stephens RS, Roffman RA, Curtin L Comparison of extended versus brief treatments for marijuana use. J Counsul Clin Psychol 68 898—908, 2000 Substance Abuse and Mental Health Services Administration The BASIS Report Marijuana Treatment Admissions Increase 1993-1999. Rockville, MB, Substance Abuse and Mental Health Services Administration, 2002a Substance Abuse and Mental Health Services Administration Results from the 2001 National Household Survey on Brug Abuse Vol I. Summary of National Findings. Rockville, MB, Substance Abuse and Mental Health Services Administration, 2002b... 

Treatment considerations for antiretroviral-experienced patients are much more complex than for patients who are naive to therapy. Prior to changing therapy, the reasons for treatment failure should be identified. A comprehensive review of the patient s severity of disease, antiretroviral treatment history, adherence to therapy, intolerance or toxicity, concomitant drug therapies, co-morbidities, and results of current and past HIV resistance testing should be performed. If patients fail therapy due to poor adherence, the underlying reasons must be determined and addressed prior to initiation of new therapy. Reasons for poor adherence include problems with medication access, active substance abuse, depression and/or denial of the disease, and a lack of education on the importance of 100%... 

Common causes of insomnia are shown in Table 72-2. In patients with chronic disturbances, a diagnostic evaluation includes physical and mental status examinations, routine laboratory tests, and medication and substance abuse histories. 

Goldstein A Brown BW (2003). Urine testing in methadone maintenance treatment applications and limitations. Journal of Substance Abuse Treatment, 25, 61-3 Gonzalez JP Brogden RN (1988). Naltrexone a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35, 192-213... 

Federal government guidelines (by NIDA-The National Institute on Drug Abuse and SAMHSA-The Substance Abuse and Mental Health Services Administration) require that companies which use commercial class drivers licenses for employees must have a testing system in place. 

Cocaine [50-36-2] - [ALKALOIDS] (Vol 1) - [ALKALOIDS] (Vol 1) -and catecholamines [EPINEPHRINE AND NOREPINEPHRINE] (Vol 9) -forensic testing for [FORENSIC CHEMISTRY] (Vol 11) -substance abuse of [PSYCHOPHARMACOLOGICAL AGENTS] (Vol 20)... 

United States Department of Health and Human Services, Substance Abuse and Mental Health Service Administration, Division of Workplace Programs. Drug Testing—Urine Drug Testing. Available online. 

BZs should be reserved for patients at low risk of substance abuse, those who require rapid relief, or those who have not responded to other therapies. Clonazepam is the most extensively studied BZ for treatment of generalized SAD. It improved fear and phobic avoidance, interpersonal sensitivity, fears of negative evaluation, and disability measures. Adverse effects include sexual dysfunction, unsteadiness, dizziness, and poor concentration. Clonazepam should be tapered at a rate not to exceed 0.25 mg every 2 weeks. Gabapentin was effective for SAD, and onset of effect was 2 to 4 weeks. j8-Blockers blunt the peripheral autonomic symptoms of arousal (e.g., rapid heart rate, sweating, blushing, and tremor) and are often used to decrease anxiety in performance-related situations. For specific SAD, 10 to 80 mg of propranolol or 25 to 100 mg of atenolol can be taken 1 hour before the performance. A test dose should be taken at home on a day before the performance to be sure adverse effects wUl not be problematic. Incomplete response to a first-line agent may benefit from augmentation with buspirone or clonazepam. 

More focused neuropsychological batteries have been developed for this purpose, such as those listed in Table 41.2. The HTV Denienda Scale is also a useful tool and only takes five minutes to administer and score (Power et al., 1995). It is important to remember that interpretation of neuropsychological tests also requires attention to patient demographics such as language skills, presence of comorbid conditions, substance abuse, and concomitant use of psychotropic medications. 

---